Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
Bent Bruun Kristensen(University of Copenhagen), Jonas Bergh(Karolinska Institutet), Marianne Ewertz(Odense University Hospital), Maj‐Britt Jensen(Aarhus University Hospital), Bent Ejlertsen, Søren Cold(Aarhus University Hospital), Brita Bjerregaard(Hospital South West Jutland), Per Edlund(Gävle Hospital), Henrik Lindman(Uppsala University), Claus Kamby(University of Copenhagen), Henning T. Mouridsen(Danish Breast Cancer Cooperative Group), Jørn Andersen(Aarhus University Hospital), Bo Nordenskjöld(Linköping University)
Cited by 71
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k